Skip to main content
F

Fujian Haixi Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 2637 HKEX Manufacturing
Open in API
Filings indexed 37 across all filing types
Latest filing 2025-10-09 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2637

About Fujian Haixi Pharmaceuticals Co., Ltd.

http://www.hxpharma.com

Fujian Haixi Pharmaceuticals Co., Ltd. is a commercial-stage pharmaceutical company integrating R&D, production, and sales capabilities. The company operates primarily under the Market Authorization Holder (MAH) framework, enabling an asset-light business model. Haixi Pharma pursues a dual-line development strategy, balancing generic drugs and innovative drugs. Its generic portfolio emphasizes first-to-file, difficult-to-imitate, and high-quality products, leveraging national pharmaceutical policies. As of late 2025, the company had 15 approved generic drugs commercialized, primarily targeting digestive system diseases and cardiovascular system diseases, with a broader therapeutic scope including oncology, ophthalmology, endocrine, nervous systems, and inflammation. The innovative drug pipeline focuses on developing small-molecule drugs with significant unmet medical needs and global market potential, exemplified by its lead program, C019199.

Recent filings

Filing Released Lang Actions
GLOBAL OFFERING
Share Issue/Capital Change Classification · 1% confidence The document is the full IPO prospectus for Fujian Haixi Pharmaceuticals Co., Ltd. (“Global Offering”), detailing the number of offer shares, offer price range, underwriting arrangements, timetable, and application procedures. This is not an earnings release or investor presentation, but the primary share issue prospectus for a new equity offering. It therefore falls under the Share Issue/Capital Change category.
2025-10-09 English
GLOBAL OFFERING
Share Issue/Capital Change Classification · 1% confidence The document is an offering announcement detailing a Global Offering for Fujian Haixi Pharmaceuticals’ IPO in Hong Kong, including the number of offer shares, pricing, timetable, and application procedures. This is not a full financial report or earnings release but an announcement of a new share issuance and listing. It therefore falls under the ‘Share Issue/Capital Change’ category.
2025-10-09 English
PHIP (1st submission)
Capital/Financing Update Classification · 1% confidence The document is a lengthy “Post Hearing Information Pack” required by the HKEX and SFC in connection with Fujian Haixi Pharmaceuticals’ proposed H-share offering and listing. It contains full prospectus-style content (expected timetable, summary, risk factors, financial information, underwriting arrangements, etc.) for a public share issuance and not merely an announcement or summary of results. Therefore it is best classified as a Capital/Financing Update, as it primarily relates to the company’s fundraising via a share offering.
2025-09-29 English
PHIP (1st submission)
Audit Report / Information Classification · 1% confidence The document is a PHIP (Post-Hearing Information Pack) from the Hong Kong Stock Exchange (HKEX). A PHIP is a preliminary document published by a company intending to list on the exchange, containing detailed business, financial, and regulatory information. Since it is a regulatory filing that does not fit into the specific categories like 10-K or IR, and serves as a general regulatory disclosure for the listing process, it is classified as a Regulatory Filing (RNS).
2025-09-29 English
OC Announcement - Appointment
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement under Hong Kong Listing Rules regarding the Company’s application for a securities offering and listing, including appointment of coordinators. It is clearly announcing a proposed share issue/IPO and related capital-raising, not a full prospectus or financial report. This fits “Share Issue/Capital Change” rather than an earnings report, management change, or regulatory fallback.
2025-08-06 English
Application Proof (1st submission)
Audit Report / Information Classification · 1% confidence The document is an 'Application Proof' for an IPO (Initial Public Offering) on the Hong Kong Stock Exchange (HKEX). It contains typical IPO prospectus sections such as 'Industry Overview', 'Business', 'Financial Information', and 'Accountants' Report'. In the context of financial filings, an IPO prospectus is classified as a 'Regulatory Filing' (RNS) as it is a formal document submitted to the exchange for regulatory approval and public disclosure, and it does not fit into the other specific categories like 10-K or IR. FY 2024
2025-08-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.